Eager to think bigger than China, Ascletis woos top Merck exec to run R&D
Having paved the way in developing and commercializing China’s first home-cultivated hepatitis C drug — with some help from a multinational pharma partner — Ascletis has now set its sight on a higher goal: To move from first-in-China to global first-in-class drugs.
Highlighting its ambition, the Hangzhou-based biotech has scooped Zhengqing Li, who has run Merck’s drug development in China for the past eight years, to become its chief medical officer and president of R&D in the country.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.